Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: Autosomal Dominant Polycystic Kidney
Interventions: Daily caloric restriction, Standard advice control; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cleft Lip, Congenital Nose Malformation, Deformity, Nose Deformities, Acquired
Interventions: Cleft Lip/Nose Repair without PSIO, Presurgical Infant Orthopedic Therapy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Months to 1 Month
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Gout
Interventions: DECT scan; Procedure
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Irvine, California • Englewood, Colorado • Wheat Ridge, Colorado + 6 more

Conditions: Smith-Magenis Syndrome (SMS)
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month to 115 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prader-Willi Syndrome
Interventions: DCCR, Placebo for DCCR; Drug
Lead sponsor: Soleno Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 20
States / cities: Orange, California • Palo Alto, California • San Diego, California + 17 more

Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevus
Interventions: tissue bonding, sutures; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mucolipidosis Type IV
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Hereditary Angioedema
Interventions: NTLA-2002, Normal Saline IV Administration; Biological
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Spina Bifida, Fecal Incontinence
Interventions: Use of the foley catheter assistive device; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Interventions: XOPH5 Ointment, Placebo; Drug
Lead sponsor: Topokine Therapeutics, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
Interventions: Not listed
Lead sponsor: House Ear Institute; Other
Eligibility: 5 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions: Losartan; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 5 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases, Mitochondrial Diseases, Mitochondrial Dysfunction, Genetic Disease
Interventions: ATI-105, Placebo; Drug
Lead sponsor: Adjuvia Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Duchenne Muscular Dystrophy
Interventions: WVE-210201 (suvodirsen), Placebo; Drug
Lead sponsor: Wave Life Sciences USA, Inc.; Industry
Eligibility: 5 Years to 12 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Cystic Fibrosis
Interventions: RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5; Device · Other
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more

Conditions: Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions: Everolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism, Multiple System Atrophy, Brain Tumor Adult, Spinal Cord Injuries, Locked-in Syndrome
Interventions: BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying, BCI-FIT language modeling; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: antitumor drug screening assay, chemotherapy, biological therapy; Other · Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Cleveland, Ohio • Milwaukee, Wisconsin

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD

Fabrication of Sequential Naso-Alveolar Molding Appliances in the Treatment of Cleft Lip/Nose Deformities

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

DECT Study in Allopurinol-Treated Gout Patients

Natural History Study of Smith-Magenis Syndrome

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

Photochemical Tissue Bonding

The Natural History and Pathogenesis of Mucolipidosis Type IV

BAX 855 PK-guided Dosing

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Enema Device for Children With Spina Bifida

Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

NF2 Natural History Consortium

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Preventing Sickle Cell Kidney Disease

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting

Patients With NMDA Biomarker Data Following Cardiac Surgery